Solmi, Marco http://orcid.org/0000-0003-4877-7233
Radua, Joaquim
Olivola, Miriam
Croce, Enrico
Soardo, Livia http://orcid.org/0000-0002-6735-0561
Salazar de Pablo, Gonzalo
Il Shin, Jae
Kirkbride, James B. http://orcid.org/0000-0003-3401-0824
Jones, Peter http://orcid.org/0000-0002-0387-880X
Kim, Jae Han
Kim, Jong Yeob
Carvalho, Andrè F.
Seeman, Mary V. http://orcid.org/0000-0001-6797-3382
Correll, Christoph U.
Fusar-Poli, Paolo http://orcid.org/0000-0003-3582-6788
Article History
Received: 6 March 2021
Revised: 28 April 2021
Accepted: 5 May 2021
First Online: 2 June 2021
Compliance with ethical standards
:
: MS has been a consultant and/or advisor to or has received honoraria from Angelini, Lundbeck. CUC has been a consultant and/or advisor to or has received honoraria from Acadia, Alkermes, Allergan, Angelini, Axsome, Gedeon Richter, Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva. He has provided expert testimony for Janssen and Otsuka. He served on a Data Safety Monitoring Board for Lundbeck, Rovi, Supernus, and Teva. He received royalties from UpToDate and grant support from Janssen and Takeda. He is also a stock option holder of LB Pharma. PF-P has received grant fees from Lundbeck and honoraria from Lundbeck, Menarini and Angelini, outside the current work. All other authors declare no conflict of interest.